Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 90

1.

Population pharmacokinetics analysis of olanzapine for Chinese psychotic patients based on clinical therapeutic drug monitoring data with assistance of meta-analysis.

Yin A, Shang D, Wen Y, Li L, Zhou T, Lu W.

Eur J Clin Pharmacol. 2016 Aug;72(8):933-44. doi: 10.1007/s00228-016-2040-2.

PMID:
27117554
2.

Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial.

Smith RC, Amiaz R, Si TM, Maayan L, Jin H, Boules S, Sershen H, Li C, Ren J, Liu Y, Youseff M, Lajtha A, Guidotti A, Weiser M, Davis JM.

PLoS One. 2016 Jan 5;11(1):e0143490. doi: 10.1371/journal.pone.0143490.

3.
4.

Atypical course in severe catatonic schizophrenia in a cannabis-dependent male adolescent: a case report.

Håkansson A, Johansson BA.

J Med Case Rep. 2015 Sep 21;9:200. doi: 10.1186/s13256-015-0678-5.

5.

Stratifying Risk for Renal Insufficiency Among Lithium-Treated Patients: An Electronic Health Record Study.

Castro VM, Roberson AM, McCoy TH, Wiste A, Cagan A, Smoller JW, Rosenbaum JF, Ostacher M, Perlis RH.

Neuropsychopharmacology. 2016 Mar;41(4):1138-43. doi: 10.1038/npp.2015.254.

PMID:
26294109
6.

Relationship between plasma homovanillic acid and outcome in patients with psychosis spectrum disorders.

van de Kerkhof NW, Fekkes D, van der Heijden FM, Egger JI, Verhoeven WM.

Neuropsychobiology. 2015;71(4):212-7. doi: 10.1159/000431095.

PMID:
26279280
7.

Uric acid levels in patients with schizophrenia on clozapine monotherapy.

Wysokiński A, Kłoszewska I.

Nord J Psychiatry. 2015 Aug;69(6):453-8. doi: 10.3109/08039488.2014.1002420.

PMID:
25801748
8.

Attention/vigilance in schizophrenia: performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS).

Nuechterlein KH, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL.

Schizophr Res. 2015 Apr;163(1-3):38-46. doi: 10.1016/j.schres.2015.01.017.

9.

Psychosis and cardiovascular disease: is diet the missing link?

Nenke MA, Hahn LA, Thompson CH, Liu D, Galletly CA.

Schizophr Res. 2015 Feb;161(2-3):465-70. doi: 10.1016/j.schres.2014.12.012.

PMID:
25560938
10.

Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study.

Correll CU, Robinson DG, Schooler NR, Brunette MF, Mueser KT, Rosenheck RA, Marcy P, Addington J, Estroff SE, Robinson J, Penn DL, Azrin S, Goldstein A, Severe J, Heinssen R, Kane JM.

JAMA Psychiatry. 2014 Dec 1;71(12):1350-63. doi: 10.1001/jamapsychiatry.2014.1314.

PMID:
25321337
11.

Verbal working memory in schizophrenia from the Consortium on the Genetics of Schizophrenia (COGS) study: the moderating role of smoking status and antipsychotic medications.

Lee J, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff DL.

Schizophr Res. 2015 Apr;163(1-3):24-31. doi: 10.1016/j.schres.2014.08.014.

12.

Serum levels of PYY(1-36) peptide in patients with schizophrenia on clozapine monotherapy.

Wysokiński A, Kowalski ML, Kłoszewska I.

Pharmacopsychiatry. 2014 Jul;47(4-5):169-73. doi: 10.1055/s-0034-1382012.

PMID:
24936806
13.

Smoking and weight among patients using clozapine.

Seppälä N, Leinonen E, Viikki M, Kampman O.

Nord J Psychiatry. 2014 Nov;68(8):620-5. doi: 10.3109/08039488.2014.907340.

PMID:
24802120
14.

Treatment of refractory substance-induced psychosis in adolescent males with a genetic predisposition to mental illness.

Rahmani M, Paul S, Nguyen ML.

Int J Adolesc Med Health. 2014;26(2):297-301. doi: 10.1515/ijamh-2013-0505.

PMID:
24762642
15.

Implementation of treatment guidelines for specialist mental health care.

Barbui C, Girlanda F, Ay E, Cipriani A, Becker T, Koesters M.

Cochrane Database Syst Rev. 2014 Jan 17;(1):CD009780. doi: 10.1002/14651858.CD009780.pub2. Review. Update in: Cochrane Database Syst Rev. 2016 Dec 15;12 :CD009780.

PMID:
24443146
16.

Reasons for cannabis use among youths at ultra high risk for psychosis.

Gill KE, Poe L, Azimov N, Ben-David S, Vadhan NP, Girgis R, Moore H, Cressman V, Corcoran CM.

Early Interv Psychiatry. 2015 Jun;9(3):207-10. doi: 10.1111/eip.12112.

17.

Risks and benefits of bupropion treatment in schizophrenia: a systematic review of the current literature.

Englisch S, Morgen K, Meyer-Lindenberg A, Zink M.

Clin Neuropharmacol. 2013 Nov-Dec;36(6):203-15. doi: 10.1097/WNF.0b013e3182a8ea04. Review.

PMID:
24201231
18.

Clinically significant drug interactions with atypical antipsychotics.

Kennedy WK, Jann MW, Kutscher EC.

CNS Drugs. 2013 Dec;27(12):1021-48. doi: 10.1007/s40263-013-0114-6. Review.

PMID:
24170642
19.

Relationship between insulin resistance, dyslipidaemia and positive symptom in Chinese antipsychotic-naive first-episode patients with schizophrenia.

Chen S, Broqueres-You D, Yang G, Wang Z, Li Y, Wang N, Zhang X, Yang F, Tan Y.

Psychiatry Res. 2013 Dec 30;210(3):825-9. doi: 10.1016/j.psychres.2013.08.056.

PMID:
24113122
20.

[Psychosis, cardiovascular risk and associated mortality: are we on the right track?].

Castillo Sánchez M, Fàbregas Escurriola M, Bergè Baquero D, Goday Arno A, Vallès Callol JA.

Clin Investig Arterioscler. 2014 Jan-Feb;26(1):23-32. doi: 10.1016/j.arteri.2013.05.006. Review. Spanish.

PMID:
23890424
Items per page

Supplemental Content

Loading ...
Support Center